NecstGen Email Formats
Pharmaceutical Manufacturing • 
Leiden, South Holland, Netherlands • 51-100 Employees
NecstGen Email Formats
NecstGen uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@necstgen.com), used 64.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@necstgen.com | 64.9% |
{first initial}.{last name} | j.doe@necstgen.com | 32.4% |
{first initial} | j@necstgen.com | 2.7% |
Key Contacts at NecstGen
Rick Hibbert
Chief Executive Officer
Martijn Glaudemans
Operations Director Contractor
Company overview
| Headquarters | Sylviusweg 62, Leiden, South Holland 2333 BE, NL |
| Website | |
| NAICS | 3254 |
| Keywords | GMP, Regenerative Medicine, AAV, Gene Therapy, DC, Cell Therapy, MSC, Process Development, Atmp, TIL, ESC, Ipsc, Oncolytic Virus, Car-T, NK, Viral Vector, Lentivirus, Viral Vector Production, Cleanroom Rental |
| Founded | 2020 |
| Employees | 51-100 |
| Socials |
About NecstGen
The Netherlands Center for the Clinical advancement of Cell and Gene Therapies (NecstGen), situated in Leiden, comprises of a state-of-the-art facility and expert knowledge for the development, production, and commercialization of Cell and Gene Therapies. NecstGen helps academic and industrial Cell & Gene Therapy developers to enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC and regulatory affairs in a brand new 4,000 m2 development & GMP manufacturing facility. We enable the next generation of therapies by translating research programs into actionalbe health solutions for patients. Our service offering: A flexible Cell and Gene Therapy manufacturing model - Full contract manufacturing services by our expert team for Cell Therapy and Viral Vector - We manufacture Pre-clinical or toxicology study material, Phase I, Phase II clinical trial material - GMP rental for any mammalian cell-based therapy type, including Cell and Viral Vector based therapies - QC, QA, and QP services supporting our cleanroom rental - Hybrid support on a flexible basis where our team compliments yours Process and assay development for Cell Therapies and Viral Vector - Process design and optimisation - Scale-up to clinically relevant volumes - Automation and closed processes - Assay development for in-process controls, release- and potency tests - Technology transfer in and out with flexibility in-mind for the future progress of your manufacturing - Consultancy-based work to advise on decision making Talk to NecstGen today about your needs for: - Induced Pluripotent Stem Cells (iPSC) - Chimeric Antigen Receptor T-Cells (CAR-T), Tumor Infiltrating Lymphocytes (TIL) T-Cell Receptor Modified T-Cells (TCR-T) - Natural Killer (NK) Cells/CAR-NK Cells - Dendritic Cells (DC) - Mesenchymal Stromal Cells (MSC) - Lentivirus (LV) - Aden-associated virus (AAV) - Oncolytic viruses - Cleanroom rental for any mammalian cell-based therapy type
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
NecstGen has 34 employees across 8 departments.
Departments
Number of employees
Funding Data
NecstGen has never raised funding before.
NecstGen Tech Stack
Discover the technologies and tools that power NecstGen's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Form builders
UI frameworks
JavaScript libraries
CDN
Analytics
UI frameworks
JavaScript libraries
JavaScript libraries
Programming languages
Blogs
Canada
Germany
United States
United Kingdom
Frequently asked questions
4.8
40,000 users
